Developer docs
API playgroundTry for free, no card

Search company profiles

GlucoTrack

Full company profile

uuid0002c7d

Namestring
GlucoTrack
Legal namestring
Glucotrack, Inc.
Websiteurl
glucotrack.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

GlucoTrack, Inc. (NASDAQ: GCTK) is a pre-revenue, clinical-stage medical device company developing a fully implantable Continuous Blood Glucose Monitoring (CBGM) system that measures glucose directly from blood rather than interstitial fluid. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics, and a mobile application, designed for up to 3-year sensor longevity with minimal calibration and no on-body wearable component. The device is investigational, limited by U.S. federal law to investigational use only, and is targeting FDA IDE clearance to enable a U.S. clinical study and a commercial launch targeted for the second half of 2026. The lead clinical data — a first-in-human study at Instituto do Coração in São Paulo (n=10, MARD 7.7%, 99% data capture, no SAEs) and a 240-day ovine study (34 devices, MARD 6.8%, no device-related adverse events) — supports the differentiated technical claim versus 7–15-day subcutaneous CGM competitors.

The company's revenue model is hardware sales of the implantable CBGM through hospital procurement channels, with implantation performed by interventional cardiologists using established percutaneous techniques. Go-to-market preparation includes dual-source U.S. contract manufacturing, an engaged U.S. CRO, an identified U.S. reimbursement pathway, ISO 13485:2016 certification (February 2025), three USPTO patents (October–November 2025), and partnerships spanning OneTwo Analytics (AI/ML analytics), TTP (independent sensor longevity characterization), the FORGETDIABETES consortium (EU bionic pancreas integration), and feasibility study sites in Brazil and Australia. The customer segments targeted are people with Type 1 or Type 2 diabetes on intensive insulin therapy, with a secondary evaluation underway in Painful Diabetic Neuropathy (PDN) via spinal cord stimulation integration.

GlucoTrack is headquartered in Rutherford, New Jersey (Delaware corporation), with historical R&D operations in Or Yehuda, Israel inherited from predecessor Integrity Applications, Inc. (renamed March 2022). The company is publicly listed but trades at an extremely compressed market capitalization (~$1.1M–$3.5M), has executed two reverse stock splits in 2025, and received Nasdaq delisting notices in May 2026, while continuing to fund clinical and regulatory milestones through a series of small public offerings and private placements totaling approximately $25M since April 2024.

Short descriptiontext

GlucoTrack is a pre-revenue, clinical-stage medical device company developing a fully implantable continuous blood glucose monitoring system that measures glucose directly from blood with up to 3-year sensor longevity, targeting people with diabetes on intensive insulin therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRutherford, United States
HQ citystring
Rutherford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous glucose monitoring, implantable medical devices, blood glucose sensors, diabetes monitoring technology, medical device development
Industry1 code
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Continuous Glucose Monitoring Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Implantable CBGM Device Sales
TypeHardware Sales
Description

GlucoTrack is pre-revenue and has not yet commercialized its CBGM technology. The company is a medical device developer targeting the continuous glucose monitoring market. The anticipated commercial model would involve the sale of implantable medical devices, likely through hospital procurement channels with reimbursement coding. The company has identified a U.S. reimbursement pathway to support commercial execution.

glucotrack.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

GlucoTrack is developing a fully implantable Continuous Blood Glucose Monitor (CBGM) system that measures glucose directly from blood in real time via an intravascular sensor lead implanted into the subclavian vein, connected to subcutaneous electronics and a mobile application. The device is designed for up to 3-year sensor longevity, eliminating the external wearable component and frequent sensor replacements required by conventional CGMs. The product is investigational (not yet FDA approved), with IDE application submitted to the FDA in May 2026 and U.S. commercial launch targeted for H2 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • MARD of 7.7% across 122 matched pairs with 99% data capture rate and no procedure or device-related serious adverse events in first-in-human clinical study (n=10, Brazil, Dec 2024-Jan 2025)
+3 more records
Product overview1 text field

GlucoTrack is developing a single unified product: the Continuous Blood Glucose Monitor (CBGM) system, which is a fully implantable device designed for long-term continuous blood glucose monitoring. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics for signal processing, and a mobile application for data display. Unlike traditional CGMs that measure interstitial fluid, the CBGM measures glucose directly from blood, eliminating lag time. The device is designed for multi-year sensor longevity (up to 3 years), with no external wearable component, representing a differentiated approach to diabetes management. The product is currently investigational and has not received FDA approval.

Product and service1 record
1Continuous Blood Glucose Monitor (CBGM)
CategoryContinuous Glucose Monitoring Devices
Description

A fully implantable continuous blood glucose monitoring system designed to measure glucose directly from blood in real time for up to 3 years. The system consists of an intravascular sensor lead implanted into the subclavian vein via established percutaneous techniques performed by interventional cardiologists, connected to subcutaneous electronics, and communicating with a mobile application for data display. Eliminates on-body wearable components and disposable sensors required by conventional CGMs, and measures directly from blood rather than interstitial fluid to eliminate lag time. The product is investigational and not yet FDA approved, with IDE application submitted May 2026.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

GlucoTrack partnered with TTP, a UK-based scientific and engineering organization, for an independent third-party study and publication on the year-long in-vitro characterization of glucose oxidase enzyme decay in electrochemical glucose sensors. The study, published in IEEE Sensors Journal (April 2026), provided externally reviewed scientific evidence supporting the feasibility of long-life implantable glucose sensors. TTP is recognized in the medtech industry for supporting life sciences and medical device innovation.

2Unnamed U.S. Clinical Research Organization (CRO)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-03-01
Description

GlucoTrack has engaged a Clinical Research Organization experienced with diabetes Medtech to manage and conduct its planned U.S. clinical study. CRO engagement is part of the company's clinical trial readiness activities for its IDE submission with the FDA.

glucotrack.com
3Unnamed Dual-Source U.S. Contract Manufacturing Partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-01
Description

GlucoTrack has established a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners for its CBGM system. This dual-source approach is intended to ensure supply chain resilience and manufacturing capacity for commercial launch.

glucotrack.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-07-01
Description

GlucoTrack initiated a feasibility clinical trial at the Diabetes Technology Research Group of St. Vincent's Hospital in Melbourne, Australia. Ethical approval was received from St. Vincent's Ethics Committee. The study provided protocol and product learnings for the planned U.S. clinical study.

5OneTwo Analytics AB
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-03
Description

GlucoTrack entered into a collaboration agreement with OneTwo Analytics AB, a Sweden-based healthtech company specializing in AI-driven analytics for diabetes data, CGM analysis, and clinical study data evaluation. The partnership leverages next-generation AI and machine learning analytics to evaluate clinical study data from GlucoTrack's CBGM technology, providing enhanced insights into performance and clinical value. OneTwo Analytics has also collaborated on the first-in-human clinical study analysis presented at ADA 2025.

glucotrack.com
6FORGETDIABETES Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-01
Description

GlucoTrack announced its participation in the FORGETDIABETES consortium, a prominent European research initiative to develop a bionic pancreas. Under this partnership, GlucoTrack's CBGM technology will be integrated with an automated insulin delivery system for a major EU diabetes study.

drugdeliverybusiness.com
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-12-01
Description

First-in-human clinical study conducted at the Interventional Cardiology department of Instituto do Coração in São Paulo, Brazil. Insertion and removal procedures were performed by interventional cardiologists using established percutaneous techniques. Study enrolled 10 participants with Type 1 or Type 2 diabetes on intensive insulin therapy.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-14
Description

Dawson James Securities acted as the sole placement agent for GlucoTrack's $10.0 million public offering in November 2024 and the $3.0 million public offering in February 2025. Capital markets advisory and securities placement services.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Market-leading CGM manufacturer (G6/G7) with dominant share in intermittent subcutaneous CGMs. Highly comparable as the benchmark GlucoTrack must displace on accuracy, longevity and patient burden; multiple GlucoTrack executives are former DexCom R&D leaders.

TypeBroad incumbent
Description

Abbott's FreeStyle Libre franchise is the global volume leader in factory-calibrated CGMs. Directly comparable as the incumbent disposable-wear CGM GlucoTrack's 3-year implantable alternative is positioned against.

TypeDirect peer
Description

Developer of the Eversense implantable CGM (180–365 day sensor, external transmitter). The closest direct peer: also a long-duration implantable CGM, also pursuing Class III PMA, and a prior employer of multiple GlucoTrack regulatory and clinical executives.

TypeBroad incumbent
Description

Medtronic's Guardian CGM integrates with its MiniMed insulin pumps for closed-loop delivery. Comparable as a CGM incumbent pursuing automated insulin delivery — the same end market GlucoTrack is targeting via the FORGETDIABETES consortium.

TypeBroad incumbent
Description

Maker of the Omnipod tubeless insulin pump, a key participant in automated insulin delivery. Comparable because GlucoTrack's CBGM is being positioned as a sensing front-end for AID systems that include Insulet-class pumps.

TypeBroad incumbent
Description

Developer of the t:slim X2 insulin pump with Control-IQ AID algorithm. Comparable as a diabetes device incumbent that consumes CGM data; a logical integration partner if GlucoTrack's CBGM reaches commercialization.

TypeEmerging player
Description

Developer of the iLet bionic pancreas system. Comparable as a fellow member/adjacent participant of the FORGETDIABETES consortium pursuing fully automated insulin delivery that will require high-accuracy continuous sensing.

TypeEmerging player
Description

Developer of the POGO Automatic blood glucose monitor — an integrated, multi-test BGM system. Comparable as another small-cap diabetes device company commercializing a differentiated glucose measurement platform; GlucoTrack's VP Marketing previously led commercial strategy there.

9OneTwo Analytics
TypeOthers
Description

Sweden-based AI/ML analytics provider for CGM and diabetes clinical study data. Comparable as GlucoTrack's core AI/data analytics partner that co-developed the first-in-human study analysis presented at ADA 2025.

TypeDirect peer
Description

Former developer of a fully implantable long-term glucose sensor. Highly comparable as a prior-generation implantable CGM platform; multiple GlucoTrack clinical and regulatory executives (Martha, Williams) came directly from GlySens and bring that institutional knowledge.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GlucoTrack

Continuous Glucose Monitoring Devicesglucotrack.com

GlucoTrack is a pre-revenue, clinical-stage medical device company developing a fully implantable continuous blood glucose monitoring system that measures glucose directly from blood with up to 3-year sensor longevity, targeting people with diabetes on intensive insulin therapy.

What GlucoTrack does

GlucoTrack, Inc. (NASDAQ: GCTK) is a pre-revenue, clinical-stage medical device company developing a fully implantable Continuous Blood Glucose Monitoring (CBGM) system that measures glucose directly from blood rather than interstitial fluid. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics, and a mobile application, designed for up to 3-year sensor longevity with minimal calibration and no on-body wearable component. The device is investigational, limited by U.S. federal law to investigational use only, and is targeting FDA IDE clearance to enable a U.S. clinical study and a commercial launch targeted for the second half of 2026. The lead clinical data — a first-in-human study at Instituto do Coração in São Paulo (n=10, MARD 7.7%, 99% data capture, no SAEs) and a 240-day ovine study (34 devices, MARD 6.8%, no device-related adverse events) — supports the differentiated technical claim versus 7–15-day subcutaneous CGM competitors.

The company's revenue model is hardware sales of the implantable CBGM through hospital procurement channels, with implantation performed by interventional cardiologists using established percutaneous techniques. Go-to-market preparation includes dual-source U.S. contract manufacturing, an engaged U.S. CRO, an identified U.S. reimbursement pathway, ISO 13485:2016 certification (February 2025), three USPTO patents (October–November 2025), and partnerships spanning OneTwo Analytics (AI/ML analytics), TTP (independent sensor longevity characterization), the FORGETDIABETES consortium (EU bionic pancreas integration), and feasibility study sites in Brazil and Australia. The customer segments targeted are people with Type 1 or Type 2 diabetes on intensive insulin therapy, with a secondary evaluation underway in Painful Diabetic Neuropathy (PDN) via spinal cord stimulation integration.

GlucoTrack is headquartered in Rutherford, New Jersey (Delaware corporation), with historical R&D operations in Or Yehuda, Israel inherited from predecessor Integrity Applications, Inc. (renamed March 2022). The company is publicly listed but trades at an extremely compressed market capitalization (~$1.1M–$3.5M), has executed two reverse stock splits in 2025, and received Nasdaq delisting notices in May 2026, while continuing to fund clinical and regulatory milestones through a series of small public offerings and private placements totaling approximately $25M since April 2024.

GlucoTrack firmographics

Firmographics
Name
GlucoTrack
Legal name
Glucotrack, Inc.
Website
https://glucotrack.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
GlucoTrack is a pre-revenue, clinical-stage medical device company developing a fully implantable continuous blood glucose monitoring system that measures glucose directly from blood with up to 3-year sensor longevity, targeting people with diabetes on intensive insulin therapy.
Ownership category
akta.pro rank

GlucoTrack industry classification

Industry
Product category
Continuous Glucose Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAA
Continuous Glucose Monitoring (CGM) Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Continuous glucose monitoring
  • Implantable medical devices
  • Blood glucose sensors
  • Diabetes monitoring technology
  • Medical device development

Where GlucoTrack is headquartered

Location

Headquarters

HQ city
Rutherford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

GlucoTrack business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Implantable CBGM Device Sales: GlucoTrack is pre-revenue and has not yet commercialized its CBGM technology. The company is a medical device developer targeting the continuous glucose monitoring market. The anticipated commercial model would involve the sale of implantable medical devices, likely through hospital procurement channels with reimbursement coding. The company has identified a U.S. reimbursement pathway to support commercial execution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

GlucoTrack product offering

Product offering

Core offering

GlucoTrack is developing a fully implantable Continuous Blood Glucose Monitor (CBGM) system that measures glucose directly from blood in real time via an intravascular sensor lead implanted into the subclavian vein, connected to subcutaneous electronics and a mobile application. The device is designed for up to 3-year sensor longevity, eliminating the external wearable component and frequent sensor replacements required by conventional CGMs. The product is investigational (not yet FDA approved), with IDE application submitted to the FDA in May 2026 and U.S. commercial launch targeted for H2 2026.

Product overview

GlucoTrack is developing a single unified product: the Continuous Blood Glucose Monitor (CBGM) system, which is a fully implantable device designed for long-term continuous blood glucose monitoring. The system comprises an intravascular sensor lead implanted into the subclavian vein, subcutaneous electronics for signal processing, and a mobile application for data display. Unlike traditional CGMs that measure interstitial fluid, the CBGM measures glucose directly from blood, eliminating lag time. The device is designed for multi-year sensor longevity (up to 3 years), with no external wearable component, representing a differentiated approach to diabetes management. The product is currently investigational and has not received FDA approval.

Differentiator

Problem solved

Functional benefit

Products and services

  • Continuous Blood Glucose Monitor (CBGM) A fully implantable continuous blood glucose monitoring system designed to measure glucose directly from blood in real time for up to 3 years. The system consists of an intravascular sensor lead implanted into the subclavian vein via established percutaneous techniques performed by interventional cardiologists, connected to subcutaneous electronics, and communicating with a mobile application for data display. Eliminates on-body wearable components and disposable sensors required by conventional CGMs, and measures directly from blood rather than interstitial fluid to eliminate lag time. The product is investigational and not yet FDA approved, with IDE application submitted May 2026.

Quantifiable outcome

  • MARD of 7.7% across 122 matched pairs with 99% data capture rate and no procedure or device-related serious adverse events in first-in-human clinical study (n=10, Brazil, Dec 2024-Jan 2025)
  • +3 more outcomes

Companies that use GlucoTrack

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

GlucoTrack technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

GlucoTrack partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • TTP (The Technology Partnership)coreStrategic or Co-development Partner · 21 April 2026GlucoTrack partnered with TTP, a UK-based scientific and engineering organization, for an independent third-party study and publication on the year-long in-vitro characterization of glucose oxidase enzyme decay in electrochemical glucose sensors. The study, published in IEEE Sensors Journal (April 2026), provided externally reviewed scientific evidence supporting the feasibility of long-life implantable glucose sensors. TTP is recognized in the medtech industry for supporting life sciences and medical device innovation.
  • Unnamed U.S. Clinical Research Organization (CRO)coreImplementation/ SI/ Consulting Partner · 1 March 2026GlucoTrack has engaged a Clinical Research Organization experienced with diabetes Medtech to manage and conduct its planned U.S. clinical study. CRO engagement is part of the company's clinical trial readiness activities for its IDE submission with the FDA.
  • Unnamed Dual-Source U.S. Contract Manufacturing PartnerscoreOEM/ Whitelabel/ Licensing Partner · 1 March 2026GlucoTrack has established a dual-source U.S. manufacturing strategy with two qualified contract manufacturing partners for its CBGM system. This dual-source approach is intended to ensure supply chain resilience and manufacturing capacity for commercial launch.
  • St. Vincent's Hospital Melbourne (Diabetes Technology Research Group)coreImplementation/ SI/ Consulting Partner · 1 July 2025GlucoTrack initiated a feasibility clinical trial at the Diabetes Technology Research Group of St. Vincent's Hospital in Melbourne, Australia. Ethical approval was received from St. Vincent's Ethics Committee. The study provided protocol and product learnings for the planned U.S. clinical study.
  • OneTwo Analytics ABcoreStrategic or Co-development Partner · 3 April 2025GlucoTrack entered into a collaboration agreement with OneTwo Analytics AB, a Sweden-based healthtech company specializing in AI-driven analytics for diabetes data, CGM analysis, and clinical study data evaluation. The partnership leverages next-generation AI and machine learning analytics to evaluate clinical study data from GlucoTrack's CBGM technology, providing enhanced insights into performance and clinical value. OneTwo Analytics has also collaborated on the first-in-human clinical study analysis presented at ADA 2025.
  • FORGETDIABETES ConsortiumcoreStrategic or Co-development Partner · 1 April 2025GlucoTrack announced its participation in the FORGETDIABETES consortium, a prominent European research initiative to develop a bionic pancreas. Under this partnership, GlucoTrack's CBGM technology will be integrated with an automated insulin delivery system for a major EU diabetes study.
  • Instituto do Coração (São Paulo, Brazil)coreImplementation/ SI/ Consulting Partner · 1 December 2024First-in-human clinical study conducted at the Interventional Cardiology department of Instituto do Coração in São Paulo, Brazil. Insertion and removal procedures were performed by interventional cardiologists using established percutaneous techniques. Study enrolled 10 participants with Type 1 or Type 2 diabetes on intensive insulin therapy.
  • Dawson James Securities, Inc.minorChannel Partner/ Reseller/ Distributor · 14 November 2024Dawson James Securities acted as the sole placement agent for GlucoTrack's $10.0 million public offering in November 2024 and the $3.0 million public offering in February 2025. Capital markets advisory and securities placement services.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

GlucoTrack competitors and assessment

Company assessment

Broad incumbents

  • DexCom: Market-leading CGM manufacturer (G6/G7) with dominant share in intermittent subcutaneous CGMs. Highly comparable as the benchmark GlucoTrack must displace on accuracy, longevity and patient burden; multiple GlucoTrack executives are former DexCom R&D leaders.
  • Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre franchise is the global volume leader in factory-calibrated CGMs. Directly comparable as the incumbent disposable-wear CGM GlucoTrack's 3-year implantable alternative is positioned against.
  • Medtronic Diabetes (Guardian / Simplera): Medtronic's Guardian CGM integrates with its MiniMed insulin pumps for closed-loop delivery. Comparable as a CGM incumbent pursuing automated insulin delivery — the same end market GlucoTrack is targeting via the FORGETDIABETES consortium.
  • Insulet Corporation: Maker of the Omnipod tubeless insulin pump, a key participant in automated insulin delivery. Comparable because GlucoTrack's CBGM is being positioned as a sensing front-end for AID systems that include Insulet-class pumps.
  • Tandem Diabetes Care: Developer of the t:slim X2 insulin pump with Control-IQ AID algorithm. Comparable as a diabetes device incumbent that consumes CGM data; a logical integration partner if GlucoTrack's CBGM reaches commercialization.

Direct peers

  • Senseonics Holdings (Eversense): Developer of the Eversense implantable CGM (180–365 day sensor, external transmitter). The closest direct peer: also a long-duration implantable CGM, also pursuing Class III PMA, and a prior employer of multiple GlucoTrack regulatory and clinical executives.
  • GlySens (acquired): Former developer of a fully implantable long-term glucose sensor. Highly comparable as a prior-generation implantable CGM platform; multiple GlucoTrack clinical and regulatory executives (Martha, Williams) came directly from GlySens and bring that institutional knowledge.

Emerging players

  • Beta Bionics: Developer of the iLet bionic pancreas system. Comparable as a fellow member/adjacent participant of the FORGETDIABETES consortium pursuing fully automated insulin delivery that will require high-accuracy continuous sensing.
  • Intuity Medical: Developer of the POGO Automatic blood glucose monitor — an integrated, multi-test BGM system. Comparable as another small-cap diabetes device company commercializing a differentiated glucose measurement platform; GlucoTrack's VP Marketing previously led commercial strategy there.

Others

  • OneTwo Analytics: Sweden-based AI/ML analytics provider for CGM and diabetes clinical study data. Comparable as GlucoTrack's core AI/data analytics partner that co-developed the first-in-human study analysis presented at ADA 2025.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

GlucoTrack social profiles

Digital presence

GlucoTrack compliance and trust

Trust signal

Compliance1 record

GlucoTrack financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GlucoTrack leadership team

Management profile

Number of profiles

Profiles7 records

GlucoTrack funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GlucoTrack M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GlucoTrack

What does GlucoTrack do?

GlucoTrack is developing a fully implantable Continuous Blood Glucose Monitor (CBGM) system that measures glucose directly from blood in real time via an intravascular sensor lead implanted into the subclavian vein, connected to subcutaneous electronics and a mobile application. The device is designed for up to 3-year sensor longevity, eliminating the external wearable component and frequent sensor replacements required by conventional CGMs. The product is investigational (not yet FDA approved), with IDE application submitted to the FDA in May 2026 and U.S. commercial launch targeted for H2 2026.

Is GlucoTrack a public or private company?

GlucoTrack is a public company. It is classified as public and is currently operating.

When was GlucoTrack founded?

GlucoTrack was founded in 2021. It employs 11 to 50 people.

Where is GlucoTrack based?

GlucoTrack is headquartered in Rutherford, United States, in the North America region.

How does GlucoTrack make money?

One revenue line is on record: implantable CBGM Device Sales.

Who are GlucoTrack's main competitors?

Broad incumbents on record are DexCom, Abbott Diabetes Care (FreeStyle Libre), Medtronic Diabetes (Guardian / Simplera), Insulet Corporation and Tandem Diabetes Care. Direct peers are Senseonics Holdings (Eversense) and GlySens (acquired). Emerging players are Beta Bionics and Intuity Medical. OneTwo Analytics is listed as an others.

Does GlucoTrack have an API?

No public API is recorded for GlucoTrack.

What industry is GlucoTrack in?

GlucoTrack's product category is Continuous Glucose Monitoring Devices. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeGLUCOTRACK INC COM PAR $0.001 Stock Short Interest Rises to 49.34% | GCTK Stock NewsShort interest in GLUCOTRACK INC COM PAR $0.001 rose to 49.34% of the float on October 30th, totaling 584,100 shares, a 303.59% increase from October 15th. Hedge fund activity shows six institutions added shares while ten reduced positions in the most recent quarter.TradingViewGlucotrack Received Notice of DelistingNasdaq notified Glucotrack on October 28, 2026, that it would delist after the closing bid price fell to $0.87 on October 14, failing an exception. Trading is suspended at the open on October 30, 2026, and the company expects OTC Markets quotation and an application for OTCID Market trading.AdvfnGlucotrack, Inc. Announces Reverse Stock SplitGlucotrack, Inc. announced a 1-for-2 reverse stock split effective October 26, 2026, reducing outstanding shares from 2,368,237 to approximately 1,184,119. The split aims to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement, with a closing bid price of at least $1.00 required until November 9, 2026.TradingViewGlucotrack Raises $2 Million Through Discounted Convertible Notes and WarrantsGlucotrack raised $2 million in a private placement by issuing senior secured convertible notes with $2.56 million in principal and warrants to purchase 8.03 million shares. The notes carry 8% annual interest, mature in nine months, and are convertible at a price tied to the stock's trading price, subject to a floor and an exchange cap pending stockholder approval. Dawson James Securities acted as placement agent for a 7% cash fee and warrants and expense reimbursement of up to $50,000.The future of tradingGlucoTrack Announces 1-for-2 Reverse Stock Split Effective October 26, 2026GlucoTrack will implement a 1-for-2 reverse stock split effective at the opening of trading on October 26, 2026, reducing outstanding common shares from 2,368,237 to approximately 1,184,119. The split aims to restore compliance with Nasdaq's $1 minimum bid price requirement, with continued listing requiring a closing bid price of at least $1 each trading day through November 9, 2026.GurufocusGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack, Inc. priced a best-efforts public offering of 169,388 shares at $2.04 per share and pre-funded warrants at $2.039 each, expecting gross proceeds of about $3.1 million. The offering is expected to close on September 25, 2026, subject to customary conditions.YahooGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack, Inc. priced a public offering of 169,388 shares at $2.04 per share, with pre-funded warrants to 1,350,220 shares at $2.039 each. The company expects to raise approximately $3.1 million in gross proceeds, with the offering expected to close on September 25, 2026.Business Wire BlogGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack, Inc. priced a best-efforts public offering of 169,388 shares at $2.04 per share and pre-funded warrants at $2.039 each. The company expects gross proceeds of about $3.1 million before fees, with closing expected around September 25, 2026.FinancialContent Business PageGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack, Inc. priced a public offering of 169,388 shares at $2.04 per share, with pre-funded warrants to 1,350,220 shares at $2.039 each. The company expects approximately $3.1 million in gross proceeds before fees, with closing expected around September 25, 2026.GlucotrackGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack priced a public offering of 169,388 shares at $2.04 each, with pre-funded warrants to 1,350,220 shares at $2.039 each. The company expects gross proceeds of about $3.1 million before fees, with closing expected around September 25, 2026.